PPARγ and RXR agonists were demonstrated to inhibit interleukin-6 (IL-6) promoter activity and reduce MMP-2 and MMP-9 expression and activity in tumor-associated fibroblasts [29]. This evidence concerns the gene IL6 and neoplasm.